UBXN11 and COVID-19: The results of pooled analysis showed that anti-IL-6 signaling agents plus SOC significantly decreased the mortality rate relative to SOC alone in patients with COVID-19 (pooled OR = 0.61, 95% CI 0.45–0.84, p = 0.002).